A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant.

Conditions

Early Triple Negative Breast Cancer

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Doxorubicin (hydrochloride)
BIOLOGICAL: Boserolimab
DRUG: Epirubicin Hydrochloride
DRUG: Cyclophosphamide
DRUG: Capecitabine
DRUG: Olaparib (if approved/available locally)

Sponsor

Merck Sharp & Dohme LLC